X
Log In
Username or E-mail:
Password:
EULA
Log In
Forgot Password
Sign Up
Sign Up
Username:
E-mail:
Password:
EULA
Sign Up
Forgot Password
Already a Member
Username or E-mail
Send Forgot Mail
Back to Login
EULA
X
Share This!
Sign Up
Log In
Logout
X
English Türkçe

KTRA

Closed

Kintara Therapeutics Inc

0.225
+0.010 (+4.64%)
Last Update: 18 Oct 2024 02:49:00
Yesterday: 0.2154
Day's Range: 0. - 0.
Send
When Written:
 
3.23
Kintara Therapeutics Inc is a clinical-stage biopharmaceutical company that focuses on the development of novel cancer therapies. The company is headquartered in San Diego, California, and was founded in 2013.

Kintara Therapeutics' lead product candidate is VAL-083, a small molecule chemotherapeutic agent that has demonstrated activity against a range of cancers, including glioblastoma multiforme (GBM), ovarian cancer, and non-small cell lung cancer. The company is currently conducting clinical trials of VAL-083 in GBM and ovarian cancer.

In addition to VAL-083, Kintara Therapeutics is developing a pipeline of other cancer therapies, including REM-001, a photodynamic therapy for the treatment of cutaneous metastatic breast cancer, and a portfolio of small molecule compounds targeting various cancer pathways.

Kintara Therapeutics is dedicated to developing innovative cancer therapies that improve patient outcomes and quality of life. The company's mission is to transform cancer treatment by advancing novel therapies that address unmet medical needs.

Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
Contact with us

Mail:
Message:
Cancel
Send
IP Adresiniz:216.73.216.11
X